PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
Schaper-Gerhardt K, Okoye S, Herbst R, Ulrich J, Terheyden P, Pföhler C, Utikal JS, Kreuter A, Mohr P, Dippel E, Satzger I, Sucker A, Schadendorf D, Ugurel S, Gutzmer R.
Schaper-Gerhardt K, et al. Among authors: gutzmer r.
Eur J Cancer. 2018 Jan;88:67-76. doi: 10.1016/j.ejca.2017.10.026. Epub 2017 Nov 28.
Eur J Cancer. 2018.
PMID: 29195116